Please use this identifier to cite or link to this item:
Title: Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease
Authors: Boronat, Mauro 
García-Cantón, César 
López-Ríos, Laura
Quevedo, Virginia
Lorenzo, Dionisio L. 
Batista, Fátima
Riaño, Marta
Nóvoa, Francisco J.
UNESCO Clasification: 32 Ciencias médicas
3205 Medicina interna
Keywords: Apolipoprotein B100,
Low-density lipoprotein–cholesterol
Non-high-density lipoprotein–cholesterol
Cardiovascular risk
Lipid goals, et al
Issue Date: 2014
Journal: Diabetes and Vascular Disease Research 
Abstract: This study analyses discordance rates between attainment of therapeutic goals for apolipoprotein B100 (apoB) and both low-density lipoprotein-cholesterol (LDL-C) and non-high-density lipoprotein-cholesterol (non-HDL-C) in a sample of 152 patients with type 2 diabetes and chronic kidney disease from Gran Canaria (Spain), using treatment targets recommended by the American Diabetes Association/American College of Cardiology (ADA/ACC), the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) and by a Spanish population-based study. Among subjects with LDL-C levels at therapeutic goal, apoB was above target in 16.3% (ADA/ACC), 6.5% (ESC/EAS) and 39.1% (population-based criteria), and among subjects with non-HDL-C levels at therapeutic goal, apoB was above target in 10.5% (ADA/ACC), 1.2% (ESC/EAS) and 29.6% (population-based criteria). These findings show that clinical management would be very differently altered depending on the criteria used to set treatment targets for apoB. Cut-off points derived from population data identify a greater number of subjects suitable for a more intensive lipid-lowering therapy.
ISSN: 1479-1641
DOI: 10.1177/1479164113511834
Source: Diabetes and Vascular Disease Research [ISSN 1479-1641],v. 11, p. 53-59
Appears in Collections:Artículos
Show full item record


checked on Nov 27, 2022


checked on Nov 27, 2022

Page view(s)

checked on Sep 17, 2022

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.